The four stages of lung tumor progression
The localization of the tumor determines lung tumor staging, that is whether it remains locally within the lungs or if tumor cells have disseminated from the lungs towards the lymph nodes or any other organs.
Stage I: The tumor is restricted to the lungs and shows no spread to any lymph nodes.
Stage II: The tumor remains within the lungs and proximal lymph nodes.
Stage III: The tumor is found within the lungs and in the lymph nodes in the middle of the chest.
Stage IV: The tumors show they spread to both lungs, the pleural tissue surrounding the lungs, or more distal areas, such as the liver and other organs.
Since the lungs are large organs, early stages of lung tumor development (such as stage I/II) are challenging to detect.
Recent advances to treat NSCLC: targeted therapy
Available anti-lung cancer therapy treatments, like most other onco-therapies, also negatively affect the viability of healthy untransformed cells, causing unwanted side effects. The rapidly evolving and novel field of targeted anti-tumor therapies has become tailored to be more specific and more efficient in eradicating tumor cells and also radically reducing the damage to normal parental tissue.
The therapy of choice for each patient is mainly based on tumor histopathology and molecular parameters such as the presence or absence of key genetic alterations. Clinical treatments for NSCLC include surgery, chemotherapy, radiotherapy, targeted drug therapy, and, recently, immunotherapy.
Standard chemotherapy has been the primary treatment option in NSCLC, but unfortunately, it is often associated with limited efficacy and overall poor patient survival. Further, since most lung cancer patients are diagnosed with advanced disease (stage III/IV), these treatments are unlikely to result in complete cures, but may however significantly improve survival and provide symptom relief.
Targeted drug therapy differs from traditional chemotherapy, which also uses drugs to treat cancer. Targeted therapies work principally by targeting specific genes, proteins, and epigenetic marks that negatively affect tumor growth and survival.
Several anti-cancer drugs targeting different proteins, undergoing clinical trials, have been developed. According to the Food and Drug Administration (FDA), there are 64 drugs approved for NSCLC and 18 drugs approved for SCLC. As a result of treatments becoming more efficient and more personalized, survival for selected groups of NSCLC patients is increasing.
Attractive therapeutic targets to treat lung cancers
The currently used targeting treatment of NSCLC in the clinic includes, among others, inhibition of targets, involved in many aspects of cancer growth and tumor blood vessel formation (angiogenesis), thus slowing cancer progression.
These therapies target several receptors signaling pathways like the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), phosphatidylinositol 3-kinase (PI3Ks), mechanistic Target Of Rapamycin (mTOR), Human Epidermal growth factor Receptor-2 (HER2), Vascular Epidermal Growth Factor Receptor (VEGFR), Kirsten Human Rat Sarcoma protein (KRAS), hepatocyte growth factor receptor (c-MET), and v-Raf murine sarcoma viral oncogene homolog B (BRAF).
Let us take a brief look at a standard (EGFR) and a promising (PI3K) therapeutic target for NSCLC.